用健康人外周血淋巴细胞,经羧甲基茯苓多糖促诱生剂制备而成的高效价临床级IL-2可用于肌注、静滴或动脉输注,IL-2与LAK细胞和化疗结合治疗晚期肿瘤44例,其中CR PR13例(29.3％),CR PR MR 22例(50％),SR16例,无效死亡6例,总有效率(CR PR MR SR)为86.4％。IL-2与~(60)Co放射综合治疗肿瘤37例,CR为51.4％,PR为46.8％,SR者例(2.7％),总有效率为97.3％,一年生存率为86.2％。应用CMP促诱生的低剂量IL-2和低剂量放/化综合治疗16例晚期癌症,CR占37.5％,总有效率(CR PR)为93.8％,一年生存率为87.5％,结果表明:该低剂量IL-2/LAK继免疫化疗与放/化疗综合治疗晚期癌症是一种有效的治疗手段。

The titer of Interleukin-2 (IL-2), prepared from the healthy human peripheral blood lymphoytes which were stimulating-induced by carboxymethy-parchymaran (CMP), was very high and reached clinical drug level after special process. The IL-2 was not only available for intramuscular injection. but also for intravenous in jection or even for intraarterial, injection 44 partients with advanced malignant tumor treated with the combination of IL-2 / LAK and chemotherapy showed an overall objective response rate to 86. 4% (CR PR: 13, 29.3%); (CR PR MR: 22, 50%); (CR PR MR SR : 38, 86. 4%) . 37 Patients with various malignant tumors were treated by low-dose interleukin-2 stinulated with CMP and irradiation with 60Co. The percentages of CR, PR and SR were 51.4%, 46.8%and 2.7%, respectively. Overall effectiveness rate was 97.3%. 1 year survival rate was 86.2%. 16 Patients with various advanced cancers were treated by low-dose interleukin-2 stimulated with CMP and low - dose radiotherapy or chemotherapy. The percentage of CR, PR and SR was 37. 5%, 56. 3%and 6 . 3%, respectively. Overall effective rate was 93. 8%. 1 year survival rate was 87. 5%. The current results indicate that the possibility of combined therapy of the low - dose IL-2/LAK adoptive chemoimmunotherapy and radiotherapy or chemotherapy may be effective in treatment of advanced cancer.

R733.7